Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
Research opens door to reveal how platelets sense mechanical forces to initiate blood clotting

Research opens door to reveal how platelets sense mechanical forces to initiate blood clotting

Using a unique single-molecule force measurement tool, a research team has developed a clearer understanding of how platelets sense the mechanical forces they encounter during bleeding to initiate the cascading process that leads to blood clotting. [More]
Scientists link malfunctioning molecular pathways to specific heart abnormalities in SCA

Scientists link malfunctioning molecular pathways to specific heart abnormalities in SCA

Patients with sickle cell anemia (SCA) develop heart complications and nearly a quarter die a sudden death. Now, researchers have linked malfunctioning molecular pathways to specific heart anomalies in SCA that result from progressive fibrosis and result in sudden death. [More]
Early initiation of prophylaxis linked to lower rates of PE and DVT in patients with severe brain injuries

Early initiation of prophylaxis linked to lower rates of PE and DVT in patients with severe brain injuries

People who sustain a traumatic brain injury (TBI) are at high risk for developing deep vein thrombosis (DVT) and pulmonary embolism (PE). PE is a leading cause of death in these patients. [More]
Novel biomarkers may offer solution for detecting autologous blood transfusion in athletes

Novel biomarkers may offer solution for detecting autologous blood transfusion in athletes

Increasing oxygen delivery to muscles can help athletes perform better and give them the edge needed to win elite competitions. One of the best ways to increase oxygen supply is through blood manipulation, undergoing a blood transfusion that provides extra red blood cells and boosts oxygen levels. [More]
UNC professor identifies research priorities to address VTE in cancer patients

UNC professor identifies research priorities to address VTE in cancer patients

More than 20 percent of all blood clots in veins occur in cancer patients. These clots, also known as venous thromboembolism (VTE), pose serious threats for cancer patients. [More]
Leader of materials technology development at Lucideon publishes third book on medical polymers

Leader of materials technology development at Lucideon publishes third book on medical polymers

Lucideon, the materials technology company, is pleased to announce that its Head of Medical Materials, Dr Xiang Zhang, has recently published his third book, Science and Principles of Biodegradable and Bioresorbable Medical Polymers. [More]
Menopause symptoms: can a healthcare professional help? An interview with Dr Heather Currie

Menopause symptoms: can a healthcare professional help? An interview with Dr Heather Currie

The survey showed that only 50% of women consulted a healthcare professional about their symptoms, despite the fact that many women said their symptoms were having a significant effect on their work life, social life, home life and sex life. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys AG announced that it has received a milestone payment from Novartis in connection with the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The antibody will be tested in the field of prevention of thrombosis. This is the twelfth therapeutic antibody based on MorphoSys's technologies that Novartis is evaluating in clinical trials. Financial details were not disclosed. [More]
Novel blood coagulation analyzer may help detect stroke risk in AF patients

Novel blood coagulation analyzer may help detect stroke risk in AF patients

Researchers at Tokyo Medical and Dental University show that an analyzer recently developed to measure blood coagulability has the sensitivity to detect hypercoagulatibility associated with stroke risk in those without atrial fibrillation [More]
Omega-3 PUFA biomarkers demonstrate benefits for fatal CHD

Omega-3 PUFA biomarkers demonstrate benefits for fatal CHD

Regular consumption of seafood and plant-based omega-3 polyunsaturated fatty acids could help lower the risk of fatal coronary heart disease, confirm findings from a pooled analysis of 19 studies. [More]
New magnetically controlled drug safe, effective in dissolving blood clots

New magnetically controlled drug safe, effective in dissolving blood clots

Critical conditions associated with the blockage of blood vessels are one of the primary health concerns worldwide. [More]
MicroRNA plays role in blocking development of arterial thrombosis

MicroRNA plays role in blocking development of arterial thrombosis

The dangers of arterial thrombosis - the formation of blood clots that can block arteries and cause illness or death - can escalate through a vicious cycle of coagulation and inflammation. [More]
New RNA aptamer can prevent pathogenic protein misfolding

New RNA aptamer can prevent pathogenic protein misfolding

Several diseases occur when mutations cause misfolding of proteins. These include "serpinopathies" which is a group of rare heritable diseases. They are caused by mutations of so-called "serpin" inhibitors of proteolytic enzymes involved in blood coagulation, tissue remodeling, and other important physiological functions. [More]
Betrixaban scores near miss for extended thromboprophylaxis

Betrixaban scores near miss for extended thromboprophylaxis

Extended thromboprophylaxis with the direct factor Xa inhibitor betrixaban just fails to show superiority to standard treatment with enoxaparin in acutely ill medical patients. [More]
SIPPET study may have implications for treatment of patients with severe hemophilia A

SIPPET study may have implications for treatment of patients with severe hemophilia A

SIPPET, a study which involved 42 centers in 14 countries in Europe, North and South America, Africa and Asia was designed to definitively settle the long-debated question whether factor VIII concentrates from different sources (plasma-derived containing VWF or recombinant technology) differ in risk of inhibitor development in previously untreated children (PUPs) with severe hemophilia A. [More]
Bare metal stents no longer advisable for high bleeding risk ACS patients

Bare metal stents no longer advisable for high bleeding risk ACS patients

A polymer-free, drug-coated stent gives markedly better outcomes than a bare metal stent in patients with acute coronary syndromes and risk factors for bleeding, report researchers. [More]
Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications. [More]
PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

PCI with polymer-free BA9 drug-coated stent better than bare metal stent in ACS patients

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention (PCI) with a polymer-free biolimus-A (BA9) drug-coated stent than with those receiving a bare metal stent (BMS) in results from a sub-study of the LEADERS FREE trial reported for the first time in a late-breaker session at EuroPCR 2016. [More]
Minihepcidins may potentially treat serious genetic blood diseases in children, adults

Minihepcidins may potentially treat serious genetic blood diseases in children, adults

New research suggests that synthetic peptides called minihepcidins may potentially treat two serious genetic blood diseases in children and adults. Although those diseases, beta-thalassemia and polycythemia vera, have opposite effects on red blood cell production, treating animals with minihepcidin helps to restore normal levels of red blood cells and reduces spleen enlargement. It also controls the accumulation of excess levels of iron in beta-thalassemia that often causes severe toxic effects. [More]
Advertisement
Advertisement